OXiGENE Inc Share Price Nasdaq
Equities
US6918284042
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2022 | - | Sales 2023 | 0.07 5.52 | Capitalization | 15.27M 1.2B |
---|---|---|---|---|---|
Net income 2022 | 5M 394M | Net income 2023 | -7M -552M | EV / Sales 2022 | - |
Net Debt 2022 | 11.02M 869M | Net Debt 2023 | 12.4M 978M | EV / Sales 2023 | 395,316,686 x |
P/E ratio 2022 |
4.5
x | P/E ratio 2023 |
-1.91
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.03% |
Managers | Title | Age | Since |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 21/04/19 |
Director of Finance/CFO | 57 | 30/06/19 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 05/01/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 10/05/20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 10/05/20 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 21/04/19 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |